MedTrace Logo

Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism

NCT00206375 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-10-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if giving growth hormone and Lupron along with thyroid hormone will improve final height in patients with long term hypothyroidism. Lupron is a medicine which is used to delay puberty and to prevent early closure of growing bones which might increase growth potential. Growth hormone is used to restore growth rate. This study will include children with "short term" and "long term" hypothyroidism.

Conditions

Interventions

DRUG

Growth hormone

Growth hormone + Synthroid + Lupron

DRUG

Growth hormone treatment and puberty

Lupron once a month and growth hormone daily

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • TAP Pharmaceutical Products Inc.

    collaborator INDUSTRY

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Parvin Yazdani, MD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2011-09-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206375 on ClinicalTrials.gov